Table 4.
Secondary Outcomes from Baseline to 12 Months*
| Variable | Usual Care Group | Nurse Management Group | Difference (95% CI) | Adjusted Difference (95% CI) |
|---|---|---|---|---|
| Hospitalizations for HF, cumulative | ||||
|
| ||||
| Persons hospitalized for HF, n | 29 | 18 | −11 | |
|
| ||||
| Persons hospitalized, %† | 14.3 | 8.9 | −5.4 (−11.6 to 0.8) | −5.2 (−11.1 to 0.7) |
|
| ||||
| Total hospitalizations for HF, n‡ | 54 | 28 | ||
|
| ||||
| Hospitalizations/person-year | 0.28 | 0.14 | −0.14 (−0.23 to −0.04) | −0.10 (−0.17 to −0.03) |
| ED visits, cumulative | ||||
|
| ||||
| Persons with any ED visit, n† | 75 | 66 | −9 | |
|
| ||||
| Persons with an ED visit, % | 36.9 | 32.5 | −4.4 (−13.7 to 4.8) | −5.7 (−15.0 to 3.7) |
|
| ||||
| Total ED visits, n‡ | 157 | 147 | −10 | |
|
| ||||
| ED visits/person-year | 0.81 | 0.76 | −0.05 (−0.23 to 0.12) | −0.06 (−0.19 to 0.07) |
| Nurse management components documented, cumulative, % (n)† | ||||
|
| ||||
| Counseled to reduce salt intake | 38.4 (78) | 47.8 (97) | 9.4 (−0.2 to 19.0) | 10.1 (0.2 to 20.0) |
|
| ||||
| Counseled to monitor weight daily | 55.7 (113) | 55.7 (113) | 0.0 (−9.7 to 9.7) | 0.3 (−10.2 to 11.0) |
|
| ||||
| Counseled to exercise | 27.6 (56) | 26.1 (53) | −1.5 (−10.1 to 7.1) | −1.0 (−11.3 to 9.2) |
|
| ||||
| Counseled against smoking | 12.8 (26) | 9.9 (20) | −3.0 (−9.1 to 3.2) | −2.7 (−7.7 to 2.3) |
|
| ||||
| Counseled to reduce alcohol consumption | 4.9 (10) | 4.4 (9) | −0.5 (−4.6 to 3.6) | −0.6 (−4.0 to 2.9) |
|
| ||||
| Referred to nutritionist | 5.4 (11) | 3.4 (7) | −2.0 (−6.0 to 2.0) | −2.4 (−6.7 to 1.8) |
| Medications prescribed (at 12 mo), %† | ||||
|
| ||||
| Vasodilators§ | 82.3 | 86.2 | 3.9 (−3.1 to 11.0) | 3.2 (−3.7 to 10.1) |
|
| ||||
| β-Blockers | 61.6 | 58.1 | −3.4 (−13.0 to 6.1) | −3.9 (−13.5 to 5.8) |
|
| ||||
| Diuretics | 74.4 | 74.9 | −0.5 (−9.0 to 8.0) | −0.5 (−9.0 to 7.9) |
*
ED = emergency department; HF = heart failure.
†
Adjusted estimates are differences in probability of the event between treatment and control groups estimated by logistic regression with site indicators as explanatory variables.
‡
Adjusted estimates are differences in events per person-year between treatment and control groups estimated by Poisson regression with site indicators as explanatory variables and survival time as the exposure variable.
§
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or hydralazine–dinitrate combination.